J. Gutierrez

Overall survival benefit for sequential doxorubicin-docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer--8-year results of the Breast International Group 02-98 phase III trial.

R. Gelber, D. Larsimont, M. Buyse, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Overall survival bene fi t for sequential doxorubicin – docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer — 8-year results of the Breast International Group 02-98 phase III trial †

D. Larsimont, M. Buyse, G. Viale, 2013 .

Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.

R. Gelber, M. Buyse, A. Goldhirsch, 2008, Journal of the National Cancer Institute.

Is risk of central nervous system (CNS) relapse related to adjuvant taxane treatment in node-positive breast cancer? Results of the CNS substudy in the intergroup Phase III BIG 02-98 Trial.

M. Gnant, G. Viale, M. Piccart-Gebhart, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Overall Survival Benefit for Sequential Doxorubicin-Docetaxel Compared to Concomitant Doxorubicin and Docetaxel in Node-Positive Breast Cancer. 8-Yr. Results of the Breast International Group (BIG) 2-98 Phase III Adjuvant Trial.

G. Viale, P. Francis, R. Jakesz, 2009 .